6533b82dfe1ef96bd1290bda
RESEARCH PRODUCT
Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA)
Grote LMcnicholas WtHedner JEsada Collaborators (Anttalainen USaaresranta TBasoglu OkGunduz CTasbakan SBouloukaki ISchiza SeBonsignore MrMarrone OPetitjean MRoisman GFietze ILaharnar NPenzel THedner JZou DGrote LKent BdMcnicholas WtRyan SKvamme JaBailly SPepin J-lTamisier RLombardi CParati GPataka APlywaczewski RSliwinski PPretl MRiha RStaats RSteiropoulos PJoppa PVerbraecken JPetiet ETrakada GLudka OBuskova JHein HDrummond MVan Zeller MDogas ZGalic TGouveris HMihaicuta SRanderath WHerkenrath SFanfulla FTestelmans Dsubject
Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyDatabases FactualPolysomnographymedicine.medical_treatmentPneumonia ViralPersonnel Staffing and SchedulingPolysomnographyDiseaseCovidsleep laboratoryBetacoronavirus03 medical and health sciencesSleep Apnea SyndromeSleep Apnea Syndromes0302 clinical medicineSurveys and Questionnairesmental disordersResearch LettermedicineHumanscardiovascular diseases030212 general & internal medicineContinuous positive airway pressurePandemicsSleep Medicine SpecialtyContinuous Positive Airway Pressuremedicine.diagnostic_testCoronavirus InfectionSARS-CoV-2business.industrySleep apneaCOVID-19Atrial fibrillationmedicine.diseaseComorbidityObesityTelemedicineEuropeSleep Medicine Specialty030228 respiratory systemHeart failureCoronavirus InfectionsbusinessDelivery of Health Caremanagementdescription
Sleep disordered breathing (SDB) is highly prevalent with a male to female predominance of two to one, and is more common in middle-aged and elderly subjects [1]. Affected patients often present with comorbidities such as obesity, cardiovascular disease (systemic hypertension, heart failure, atrial fibrillation), and diabetes mellitus Type II [2]. The strong overlap between the profile for SDB patients and the identified risk factors for adverse outcomes of COVID-19 infection that include age, male gender, and cardio-metabolic comorbidity [3] suggest that SDB patients may benefit from effective therapy if confronted with COVID-19 infection [4].
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-05-04 | European Respiratory Journal |